Insulin signalling: new target for Parkinson's treatments?

Affiliations

¹ Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria. Electronic address: werner.poewe@i-med.ac.at.
² Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria.

Comment

Werner Poewe et al. Lancet. 2017.

. 2017 Oct 7;390(10103):1628-1630.

doi: 10.1016/S0140-6736(17)32101-3. Epub 2017 Aug 3.

¹ Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria. Electronic address: werner.poewe@i-med.ac.at.
² Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT-6020 Innsbruck, Austria.

No abstract available

Comment on

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Athauda D, et al. Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3. Lancet. 2017. PMID: 28781108 Free PMC article. Clinical Trial.